Cargando…

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer

Until recently, few therapeutic options were available for patients with castration-resistant prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated benefit (sipuleucel-T, cabazitaxel, abiraterone, and denosumab) have been approved in this setting, and to-date several other agent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adamo, Vincenzo, Noto, Laura, Franchina, Tindara, Chiofalo, Giuseppe, Picciotto, Maria, Toscano, Giuseppe, Caristi, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364443/ https://www.ncbi.nlm.nih.gov/pubmed/22666217 http://dx.doi.org/10.3389/fendo.2012.00073

Ejemplares similares

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer
por: Russo, Alessandro, et al.
Publicado: (2017)

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
por: Russo, Alessandro, et al.
Publicado: (2019)

Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer
por: Harris, Anna E., et al.
Publicado: (2022)

A Changing Landscape in Castration-Resistant Prostate Cancer Treatment
por: Felici, A., et al.
Publicado: (2012)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis
por: Puliafito, Ivana, et al.
Publicado: (2023)

CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
por: Chen, Xi, et al.
Publicado: (2022)

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012)

Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
por: Liu, Min, et al.
Publicado: (2023)

Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
por: Patel, Jesal C., et al.
Publicado: (2013)

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study
por: Pergolizzi, Stefano, et al.
Publicado: (2011)

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2018)

The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
por: Adamo, Barbara, et al.
Publicado: (2017)

Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
por: Adamo, Barbara, et al.
Publicado: (2019)

Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment
por: Aggarwal, Rahul, et al.
Publicado: (2011)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
por: Alkhudair, Nora A.
Publicado: (2019)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2016)

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis
por: Zhang, Xianlu, et al.
Publicado: (2023)

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
por: Armandari, Inna, et al.
Publicado: (2014)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Henríquez, Iván, et al.
Publicado: (2021)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
por: Imamura, Yusuke, et al.
Publicado: (2016)

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
por: Arshad, Osama Ali, et al.
Publicado: (2017)

Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer
por: Beer, Tomasz M., et al.
Publicado: (2022)

Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
por: Amaral, Teresa Maria Santos, et al.
Publicado: (2012)

Targeting the MLL complex in castration resistant prostate cancer
por: Malik, Rohit, et al.
Publicado: (2015)

Targeting hexokinase 2 in castration-resistant prostate cancer
por: Deng, Yibin, et al.
Publicado: (2015)

Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
por: Zhong, Shangwei, et al.
Publicado: (2021)

Castration-resistant prostate cancer: systemic therapy in 2012
por: Maluf, Fernando C., et al.
Publicado: (2012)

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
por: Liu, Hsin-Ho, et al.
Publicado: (2014)

Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
por: Russo, Alessandro, et al.
Publicado: (2018)

Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer
por: Moon, Sue Jin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d8hb5el5t41m4pc8fa2q7ornon